Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020

NEXT STORY
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
PREV STORY
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita® (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021

author_avatar
NASDAQ Market News

FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program

FREMONT, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), ...

author_avatar
NASDAQ Market News

Newly Launched Disinfecting System Reduces Hospital Acquired Infections

LITTLE RIVER, S.C., May 16, 2018 (GLOBE NEWSWIRE) -- PCT LTD, formerly Bingham Canyon ...

author_avatar
NASDAQ Market News